Sciwind’s GLP‑1 data highlight Chinese firms' metabolic ambitions

Sciwind Biosciences has shared late-stage trial data for its injectable GLP-1 therapy, signaling an intensifying bid to challenge incumbents like Eli Lilly (NYSE: LLY) and Novo Nordisk (NOV: N) in the global obesity drug market.

At the 85th American Diabetes Association Scientific Sessions, the Hangzhou-based biotech presented Phase III data for ecnoglutide, its once-weekly GLP-1 receptor agonist. After 48 weeks, the therapy achieved a mean weight loss of 15.4% among Chinese adults with overweight or obesity. Almost 93% of participants saw at least 5% weight reduction, with nearly 64% achieving a drop of 15% or more.

The trial, known as SLIMMER, enrolled 664 adults across 36 sites in China. Sciwind’s candidate works through a novel mechanism that selectively activates cAMP signaling while reducing β-arrestin engagement—potentially improving tolerability and sustaining efficacy. Side effects were generally mild and aligned with those seen in other GLP-1 therapies.